BMS CA224-098, RELATIVITY 098 (Melanoma)
What is the Purpose of this Study?
- Be randomly assigned (like a coin flip) to 1 of 2 groups
-- One group will get relatlimab + nivolumab after surgery
-- The other group will get nivolumab on its own after surgery
- Both groups will get dosed every 4 weeks by intravenous (IV) infusion for up to 1 year
Who Can Participate in this Study?
Adults ages 18+ who:
- Are diagnosed with stage III or 4 melanoma
- Have had their tumor(s) completely removed
For more information about who can join this study, please contact the study team at email@example.com.
What is Involved?
We are doing this study to find out if combining 2 drugs (relatlimab + nivolumab) is more effective than using nivolumab on its own to prevent a recurrence of melanoma. Currently, using nivolumab on its own is the standard treatment to prevent melanoma from coming back after it has been removed by surgery.